Open Access

PTEN inhibitor VO‑OHpic suppresses TSC2‑/‑ MEFs proliferation by excessively inhibiting autophagy via the PTEN/PRAS40 pathway

  • Authors:
    • Wenda Wang
    • Xu Wang
    • Hao Guo
    • Yi Cai
    • Yushi Zhang
    • Hanzhong Li
  • View Affiliations

  • Published online on: March 31, 2020     https://doi.org/10.3892/etm.2020.8629
  • Pages: 3565-3570
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tuberous sclerosis complex (TSC) is a relatively rare autosomal dominant disease which involves multiple organs, including the brain, kidney, lung, skin and heart. Renal angiomyolipomas (RAML) are the main causes of mortality in patients with TSC. The preferred treatment for RAML is the use of mTOR inhibitors, but the efficacy of these are not satisfactory. Therefore, an alternative treatment is urgently required. Autophagy levels decline in TSC associated cortical tubers, and the inhibition of autophagy in animal or cell models of TSC may suppress tumor development and cell proliferation. PTEN is a protein tyrosine phosphatase and can inhibit the activation of Akt. In the present study, it was indicated that the PTEN inhibitor, hydroxyl(oxo)vanadium 3‑hydroxypiridine‑2‑carboxylic acid (VO‑OHpic), suppressed proliferation and growth of TSC2‑/‑ murine embryonic fibroblasts (MEFs) by further inhibiting autophagy of cells. The expression levels of human microtubule‑associated protein 1 light chain 3‑I (LC3‑I) and LC3‑II, which are autophagy associated proteins, were demonstrated to decline following VO‑OHpic treatment. The expression levels of phosphorylated proline‑rich Akt substrate 40 kDa (PRAS40) also decreased in TSC2‑/‑ MEFs treated with VO‑OHpic. The PTEN inhibitor may inhibit the proliferation of TSC2‑/‑ MEFs through the PTEN‑PRAS40 pathway by excessively inhibiting autophagy, without the dependence of the Ras homolog, mTORC1 binding/mTOR pathway. PTEN may be a potential therapeutic target for the treatment of TSC. Further in vivo studies are required to confirm these results.
View Figures
View References

Related Articles

Journal Cover

June-2020
Volume 19 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang W, Wang X, Guo H, Cai Y, Zhang Y and Li H: PTEN inhibitor VO‑OHpic suppresses TSC2‑/‑ MEFs proliferation by excessively inhibiting autophagy via the PTEN/PRAS40 pathway. Exp Ther Med 19: 3565-3570, 2020.
APA
Wang, W., Wang, X., Guo, H., Cai, Y., Zhang, Y., & Li, H. (2020). PTEN inhibitor VO‑OHpic suppresses TSC2‑/‑ MEFs proliferation by excessively inhibiting autophagy via the PTEN/PRAS40 pathway. Experimental and Therapeutic Medicine, 19, 3565-3570. https://doi.org/10.3892/etm.2020.8629
MLA
Wang, W., Wang, X., Guo, H., Cai, Y., Zhang, Y., Li, H."PTEN inhibitor VO‑OHpic suppresses TSC2‑/‑ MEFs proliferation by excessively inhibiting autophagy via the PTEN/PRAS40 pathway". Experimental and Therapeutic Medicine 19.6 (2020): 3565-3570.
Chicago
Wang, W., Wang, X., Guo, H., Cai, Y., Zhang, Y., Li, H."PTEN inhibitor VO‑OHpic suppresses TSC2‑/‑ MEFs proliferation by excessively inhibiting autophagy via the PTEN/PRAS40 pathway". Experimental and Therapeutic Medicine 19, no. 6 (2020): 3565-3570. https://doi.org/10.3892/etm.2020.8629